Logo

Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Share this

Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Shots:

  • The companies collaborated to investigate oral delivery of Sanofi's Nanobody based medicines- which are currently available in IV & SC formulations
  • The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases
  • Sanofi provides seed funding to i20 in Apr’2020 while the company received strategic investment from Colorcon Ventures in Dec’2020

 ­ Ref: Businesswire | Image: Businesswire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions